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INTRODUCTION
PTH is a major regulator of calcium metabolism which defends against hypocalcemia, in part by stimulating bone resorption and thereby the release of calcium from the skeleton. However when injected daily, a regimen known as intermittent PTH (iPTH) treatment, the hormone markedly stimulates bone formation leading to improved bone microarchitecture and increased strength 1 . As a result, intermittent treatment with the 1-34 fragment of PTH is an FDA approved treatment modality for postmenopausal osteoporosis. In addition, PTH has important effects on the hemopoietic system. PTH expands the HSPC pool and regulates the activity of the HSPC niche 2 , the specialized microenvironment that maintains HSPCs. Accordingly, patients with primary hyperparathyroidism have an increased number of circulating BM-derived HSPCs in the peripheral blood 3 . Moreover, some PTH regimens increase the population that can later be mobilized by G-CSF 4 , while others induce mobilization of progenitor cells from the BM into the peripheral circulation 5 , thus mimicking the effects of G-CSF. Because of these properties, PTH has been investigated as a potential therapeutic agent to enhance HSPCs mobilization 6 .
However, the mechanism by which PTH increases the number of HSPCs has only been partially elucidated. Limited data 4 have addressed whether PTH regulates the most primitive long-term reconstituting subset of HSPCs (LT-HSPCs), or the short-term reconstituting subset of HSPCs (ST-HSPCs), a population which arise from LT-HSPCs and possess limited self-renewal activity 7 .
A pivotal effect of PTH is that of increasing the HSPC pool through regulatory actions on the HSPC niche. The HSPC niche comprises a variety of cells including SCs and osteoblasts (OBs) 8 . Early studies had linked this activity of PTH to its capacity to increase the osteoblastic expression of the Notch ligand, Jagged1, leading to the activation of Notch signaling in HSPCs in vivo 2 . PTH directly upregulates the expression of Jagged1 mRNA in OBs 9 . In addition,
Jagged1 is upregulated in stromal cells (SCs) when canonical Wnt signaling is activated
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Another intracellular system that regulates HSPC expansion is canonical Wnt signaling [13] [14] [15] .
PTH activates Wnt signaling in SCs and OBs through multiple mechanisms which include Wnt ligand-independent activation of the Wnt coreceptor LRP6 16 , increased production of Wnt ligands by bone and BM cells 17 , and suppression of sclerostin production 18 .
While SCs, OBs and osteocytes represent the major targets of PTH in bone [19] [20] [21] , reports from our laboratory have disclosed that T lymphocytes play an unexpected role in the mechanism of action of PTH in bone [22] [23] [24] [25] . Importantly, treatment with daily PTH increases the T cell production of Wnt10b 23,25 , a Wnt ligand that stimulates osteoblastogenesis by activating Wnt signaling in SCs and OBs 23 , through direct targeting of the T cell PPR receptor 25 . As a result, the bone anabolic activity of daily PTH treatment is markedly reduced in T cell-deficient mice and in mice with a specific disruption of Wnt10b production by T cells 23 .
While T cells contribute to the actions of PTH in bone, the effects of this hormone in other organs are completely T cell independent. For example, the finding that T cell deficient mice possess normal serum levels of calcium and phosphate and a significant increase in serum calcium but not in bone resorption in response to PTH treatment 22 indicate that T cells are not required for PTH to exerts its effects in the kidney.
The lack of information on whether T cells contribute to the effects of PTH on HSPCs prompted us to investigate the role of T cells in the mechanism by which PTH acts on HSPCs.
We show that direct activation of PPR signaling in T cells is required for PTH to expand STHSPCs. The involved mechanism hinges on the capacity of PTH to induce T cell production of Wnt10b, a Wnt ligand critical for the activation Wnt signaling in both SCs and HSPCs. T cell transfer . WT spleen T cells purified by negative immunoselection using MACS Pan T cell isolation kit (Miltenyi Biotech, Auburn, CA) were injected (5 × 10 6 cells per mouse) IV into TCRβ-/-recipient mice 3 weeks before treatment. Successful T cell engraftment was confirmed by flow cytometry of the spleens of the recipient mice harvested at sacrifice.
SC purification. BM were collected from mice treated with Veh or PTH for 4 weeks and SCs were purified as previously described 22, 25 . Additional information is provided on line as supplemental methods.
Flow cytometry and cell sorting.
Methods and reagents are described on line as supplemental methods. were housed in sterilized microisolator cages and received sterilized chow and autoclaved water (pH 3.0). Recipient mice were killed at 8 weeks after transplantation, and the reconstitution in spleen, blood, and BM was analyzed by flow cytometry using the lineage markers B220, CD11b, Gr-1, and CD3.
Real
For competitive transplantation assays, mice expressing the marker CD45.2 were treated with vehicle or iPTH for 4 weeks. BM cells (2.5x10 5 ) from treated C57Bl/6, TCRβ-/-, T cell reconstituted TCRβ-/-, and Wnt10b-/-mice were mixed with BMCs (5x10 5 ) from B6.SJL mice expressing the marker CD45.1 to obtain 1:2 competition and intravenously injected in CD45.1-expressing recipient mice. Recipient mice (8-10 weeks old) were lethally irradiated as described above. Repopulation was evaluated at the times indicated after transplantation in peripheral blood by flow cytometry using the hemopoietic makers CD45.1, CD45.2, CD11b, B220, Gr-1, and CD3. The primary recipients were killed 36 weeks after transplantation and the BMCs were analyzed for the population of LSK cells and used for secondary transplantation.
For secondary transplantation, BM cells from primary recipients were mixed with BM cells from a competitor animal expressing the marker CD45.1 at a ratio of 1:2. A total of 7.5x10 5 cells were transplanted into lethally irradiated CD45.1-expressing secondary recipients. Peripheral blood from the secondary recipients was analyzed at the times indicated after transplantation by flow cytometry using the hemopoietic makers as previously described. The secondary recipients were killed after 12 weeks transplantation and the reconstitution in spleen, BM was analyzed. 
RESULTS

In vivo iPTH treatment expands ST-HSPC/multipotent progenitors (MPPs) through T cells
In vivo PTH treatment is known to increase the Lin-Sca-1+c-kit+ (LSK) population of hemopoietic progenitors 2 . To determine whether T lymphocytes are required for intermittent PTH to exert its effects on HSPCs, 6 week old wild type (WT) and congenic TCRβ-/-mice, a strain completely devoid of αβ T cells, were injected daily with vehicle or 80 μg/kg of hPTH 1-34 for 4 weeks, a treatment modality referred to hereafter as iPTH. To control for strain dependent confounders, the study included TCRβ -/-mice subjected to adoptive transfer of WT T cells 3 weeks before initiation of iPTH treatment, a procedure that is followed by the engraftment and homeostatic expansion of the donor T cells 23, 24 .
Flow cytometric analysis of splenocytes harvested at sacrifice from mice subjected to adoptive transfer of T cells confirmed the engraftment and the expansion of adoptively transferred T cells (Supplemental Fig. 1 ). Analysis of BM samples revealed that vehicle treated WT mice, TCRβ-/-mice, and TCRβ-/-mice reconstituted with T cells had a similar number of BM mononucleated cells (BMMCs) and LSK cells (Supplemental Fig. 2 ) and a similar relative frequency of LSK cells (Fig. 1a-c) . Treatment by iPTH caused a ~ 2 fold increase in the relative number LSK cells of WT and reconstituted TCRβ-/-mice (Fig. 1a,c) , while there was no effect in BM samples from T cell deficient TCRβ-/-mice (Fig. 1b) . These findings demonstrate that T cells are required for iPTH to expand the LSK population. Confirming earlier reports 2, 28 , iPTH had no effects on more differentiated lineages of the peripheral blood (Supplemental Fig. 3 ).
The LSK compartment of the BM contains at least three populations of cells with multilineage potential but progressively limited self-renewal. These populations include LT-HSPCs, ST- 30 . We found that in vivo iPTH treatment increased the frequency of ST-HSPC/MPPs in BM samples from WT mice and TCRβ-/-mice subjected to adoptive transfer of WT T cells (Fig.   1d,f) , while it had no effects in BM samples from TCRβ-/-mice (Fig. 1e) . By contrast, iPTH did not increase the frequency of LT-HSPCs in T cell replete and T cell deficient mice. Together, these data indicate that iPTH expands HSPCs with limited self-renewal through T cells. (Fig. 2a,b) . However the engraftment advantage conferred by iPTH treatment was no longer evident at week 8 after transplantation for the myeloid and granulocytic lineages (Fig. 2c) , and at 12 weeks after transplantation for the B cell lineage (Fig. 2d) (Fig. 2a,f ). These findings demonstrate that T cells are required for iPTH to expand ST-HSPCs.
Stimuli that lead to the expansion of the ST-HSPC pool may cause depletion of the LT-HSPC pool 32 . To investigate whether iPTH depletes LT-HSPCs secondary transplantation were performed 36 weeks after the primary transplantation. At this time point after transplantation the relative frequency of donor derived LSK cells (CD45.2+ LSKs) in the BM of primary recipients was the same in mice that received BM from vehicle or iPTH treated donors (Fig. 2g) .
Engraftment in the secondary recipients was measured at 10 weeks, a time point when iPTH no longer induced engraftment superiority in the primary recipients. We found that the peripheral blood of secondary recipients that were transplanted with BM derived from iPTH treated mice demonstrated equal reconstitution all compartment, as compared to recipients transplanted with BM from vehicle treated donors ( 
PPR signaling in T cells is required for iPTH to expand HSPCs and increase survival after BM transplantation
To determine whether this stimulatory effect of PTH on HSPCs is due to direct PPR signaling (Fig. 4g,h ). In a second set of experiments donor mice were treated with vehicle or iPTH for the 4 weeks before the BM harvest, while recipient mice were left untreated (Fig. 4i,j) . These studies revealed that treatment with iPTH of either donor or recipient mice increased by ~3 fold the survival at 4 weeks of recipients transplanted with control BM. By contrast PTH had no effect on the survival of mice transplanted with BM from PPR T cells -/-mice.
These data demonstrate that direct activation of the PPR receptor in T cells is required for iPTH to affect the function of HSPCs during myeloablative recovery.
T cells regulate HSPCs through Wnt10b.
Treatment with iPTH increases the T cell production of Wnt10b 23,25 while activation of Wnt signaling in both SCs and HSPCs promotes HSPC expansion and self-renewal [13] [14] [15] . Therefore we sought to investigate whether iPTH activates Wnt signaling in SCs and HSPCs through T cell produced Wnt10b. In a first set of experiments we harvested SCs from mice treated with vehicle or iPTH for 4 weeks and then analyzed the mRNA expression of genes specifically upregulated by Wnt signaling. The analyzed genes were chosen, as they are sensitive markers of Wnt activation 35 . The analyzed genes were: aryl-hydrocarbon receptor (Ahr), axin2, cysteine rich protein 61 (Cyr61), naked cuticle 2 homolog (Nkd2), transgelin (tagln), transforming growth factor β3 (TGFβ3), thrombospondin 1 (Thbs1), Twist gene homolog 1 (Twist1) and Wnt1 inducible signaling pathway protein 1 (Wisp1). Analysis of purified SCs revealed that the levels of mRNA for the 9 tested genes were all increased by iPTH in SCs from T cell replete mice and T cell deficient mice previously subjected to adoptive transfer of WT T cells (Fig. 5a,c) . By contrast iPTH did not increase the expression of Wnt dependent genes in SCs from T cell deficient ( Fig. 5b ) and Wnt10b null mice (Fig. 5e ). Attesting to the specific role of T cell produced Wnt10b, iPTH also failed to upregulate the expression of Wnt dependent genes in T For personal use only. on September 14, 2017. by guest www.bloodjournal.org From cell deficient mice previously reconstituted with T cells from Wnt10b-/-mice (Fig. 5d) . Thus, T cells and their production of Wnt10b are required for iPTH to activate Wnt signaling in SCs.
Next HSPCs were purified by FACS sorting from the BM of mice treated with vehicle and iPTH for 4 weeks and assessed the expression of Wnt dependent gene. We again found that the levels of mRNA for the 9 tested genes were all increased 2-3 fold by iPTH in HSPCs from WT mice (Fig. 6a) , and T cell deficient mice previously subjected to adoptive transfer of WT T cells (Fig. 6c) . By contrast iPTH did not increase the expression of Wnt dependent genes in HSPCs from T cell deficient (Fig. 6b) , T cell deficient mice previously reconstituted with T cells from Wnt10b-/-mice (Fig. 6d) , and Wnt10b null mice (Fig. 6e) . These data indicate that iPTH upregulates Wnt signaling in HSPCs through T cell produced Wnt10b.
To further investigate the hypothesis that T cells regulate HSPCs expansion through Wnt10b,
we assessed the effects of iPTH on the number of LSK cells in WT mice, Wnt10b-/-mice and TCRβKO mice previously reconstituted with Wnt10b-/-T cells. Analysis by flow cytometry revealed that iPTH increased by ~ 2 fold the frequency of LSK cells in the BM of WT mice while it had no effect in BM from Wnt10b-/-mice and TCRβKO mice reconstituted with Wnt10b-/-T cells (Fig. 7a) . Analysis of SLAM markers expression revealed that iPTH expands STHSPCs/MPPs in WT mice but not in Wnt10b-/-mice and TCRβKO mice reconstituted with Wnt10b-/-T cells (Fig. 7b) , thus demonstrating that iPTH expands STHSPCs/MPPs through T cell produced Wnt10b. As expected, IPTH did not cause the expansion of LT-HSPCs in all mice (Fig. 7c) To obtain additional confirmation of the specific role of Wnt10b, a constitutively active (ca) form of Wnt10b was expressed in WT BM cells using a retroviral expression vector 36 . BM cells expressing caWnt10b were transplanted into lethally irradiated WT recipients. Mock-transduced BM cells were used as controls. Eight weeks post transplantation Wnt10b mRNA levels were higher in BM cells from mice transplanted with caWnt10b BM as compared to those transplanted with control BM (Supplemental Fig. 5a ). Analysis by flow cytometry revealed that mice transplanted with caWnt10b BM cells had ~ 2 fold higher relative number of LSK cells than mice transplanted with control BM cells (Supplemental Fig. 5b,c) .
Additional competitive repopulation assays were then conducted using WT and Wnt10b-/-mice. CD45.2+ WT mice and Wnt10b-/-mice were treated with iPTH or vehicle for 4 weeks.
Their BM was then mixed with BM from untreated CD45.1+ WT mice at a ratio of 1:2 and injected into lethally irradiated CD45.1+ host mice. Analysis of host peripheral blood at 2-24
weeks revealed an increase in the engraftment of cells from iPTH treated WT mice at weeks 2 and 4, as compared to cells from vehicle treated WT mice ( Fig. 7d-f ). By contrast iPTH did not increase the engraftment of cells from Wnt10b-/-mice at any time point, thus demonstrating that Wnt10b is required for iPTH to expand ST-HSPCs.
To assess the relevance Wnt10b dependent expansion of HSPCs we assessed the effect of PTH on the survival of lethally irradiated mice after transplantation of BM derived from WT and Wnt10b-/-mice. In a first experiment donor mice were left untreated while recipient mice were treated with vehicle or iPTH for 4 weeks starting the day of the BM transplantation (Fig. 7g,h ).
In a second set of experiments donor mice were treated with vehicle or iPTH for the 4 weeks before the BM harvest, while recipient mice were left untreated (Fig. 7i,j) . These studies revealed that treatment with iPTH of either donor or recipient mice increased by ~3 fold the survival at 4 weeks of recipients transplanted with WT BM. By contrast PTH had no effect on the survival of mice transplanted with BM from Wnt10b-/-mice. Thus, T cells and Wnt10b are required for iPTH to activate Wnt signaling in HSPCs and increase survival after BM transplantation.
T cell-independent mechanisms have been proposed by others to explain the effects of iPTH on HSPCs. Increased expression of Jagged1 by SCs was the first such mechanism to be identified 2 . To determine whether T cells participate in this regulatory mechanism we examined the expression of Jagged1 mRNA in SCs from various strains of mice treated with vehicle or iPTH. These experiments revealed that iPTH increases by ~4 fold the expression of Jagged1 mRNA in SCs from WT mice and TCRβ-/-previously reconstituted with WT T cells. By contrast iPTH did not increase Jagged1 expression in SCs from TCRβ-/-mice, TCRβ-/-mice previously reconstituted with Wnt10b-/-T cells, and Wnt10b -/-mice (Supplemental Fig. 6 ). These data suggest that T cell production of Wnt10b is required for iPTH to upregulate Jagged1 in SCs.
For Confirming an earlier report 4 , we also found that iPTH has no negative effects on long-term A previously unreported finding of our study is that direct, ligand-dependent activation of PPR signaling in T cells and the resulting production of Wnt10b are required for iPTH to expand HSPCs. This conclusion is supported by the observation that deletion of T cells or silencing of PPR signaling in T cells blocks the expansion of HSPCs induced by iPTH. Attesting to the translational relevance of these observations we found that the lack of T cells, or of PPR signaling in T cells, prevents iPTH treatment from increasing the survival of lethally irradiated mice subjected to BM transplantation.
Although direct, Wnt10b independent effects of T-cells on HSPCs cannot be excluded, our data point to a pivotal mechanistic role of T cell produced Wnt10b as mediator of the effects of iPTH in HSPCs. The relevance of Wnt10b was demonstrated by the novel findings that iPTH fails to activate Wnt signaling in SCs and HSCs and expand ST-HSPC in mice specifically lacking T cell production of Wnt10b. Another relevant finding of this study is that iPTH does not improve survival after BM transplantation in Wnt10b-/-mice. Previous reports from our laboratory had disclosed that treatment with iPTH induces a blunted bone anabolic response in mice with a global 25 and a T cell specific deletion of Wnt10b production 23 . Therefore, the findings of the current study together with earlier reports from our laboratory 23,25 demonstrate that Wnt10b is a central common mediator of the effects of iPTH on HSPCs and bone.
However, it should be underscored that not all of the effects of PTH are mediated by T cells and Wnt10b. In fact, T cell deficient mice not only display a significant residual bone response to iPTH, but also possess a normal renal response to PTH 22 .
Our results are in keeping with those of earlier studies on the role of Wnt signaling in HSPC .
A finding of the current study is that T cell production of Wnt10b is required for iPTH to upregulate the expression of Jagged1 in SCs. Therefore, iPTH
upregulates Jagged 1 expression in SCs, via a stimulatory effect on the production of Wnt10b by T cells. However, direct stimulation of osteoblastic Jagged1 by PTH or constitutively activation of PPR signaling in OBs has been reported 2, 9 . These findings are not in contrast with the results of the current study because activation of PPR signaling in OBs is likely to stimulate osteoblastic production of Wnt10b via a cAMP dependent mechanism 48 . Therefore it is likely that activation of PPR signaling in both osteoblastic cells and T cells contribute to the local increase in Jagged1 in response to iPTH.
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